The United States Food and Drug Administration’s (FDA) advisory committee voted on Tuesday to recommend Novavax's COVID-19 vaccine for use in the US.
After a meeting where the jab's safety and effectiveness data were discussed, the FDA's committee voted 21-0 with one abstention in favor of the vaccine for those 18 and older. Should the FDA decide to follow this recommendation, the Novavax two-dose vaccine, which relies on a more traditional approach than the vaccines from Moderna and Pfizer-BioNTech, would become the fourth shot to win clearance for adults in the United States.
Novavax confirmed earlier today that Nasdaq put this biotechnology company's stock trading on hold, ahead of the FDA's meeting.
